Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agios Pharm (AGIO)
The Agios Pharm share price today is 28.00, view NASDAQ AGIO stock exchange data. Track the latest Agios Pharm share price with real-time updates on AGIO stock performance including market cap, day range, 52-week range and dividend yield. Access AGIO charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.71
28.68
52 wk Range
22.24
46.00
AGIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.7128.68
52 wk Range
22.2446.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
41.13
Upside
+46.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Agios Pharm For: 29 April
- Investing.com
- Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 41.13
(+46.88% Upside)
Agios Pharm SWOT Analysis
Pyrukynd's Promise | Explore Agios's lead drug candidate Pyrukynd, potentially the next treatment for thalassemia and sickle cell disease, awaiting FDA decision by September 2025 |
Financial Fortitude | With $1.4 billion in cash and a robust financial health score, Agios stands well-positioned to fund its ambitious drug development pipeline |
Market Dynamics | Delve into Agios's competitive landscape, including challenges from Novo Nordisk's etavopivat and emerging liver safety signals for Pyrukynd |
Analyst Outlook | Analyst price targets range from $38 to $71, with an average of $56.25, suggesting potential upside from the current $30.11 trading price |
Agios Pharm Earnings Call Summary for Q1/2026
- Q1 2026 EPS of -$1.69 beat estimates by 6.63%; revenue of $18.8M exceeded forecasts by 35.15%, driven by AQVESME's thalassemia launch
- Net revenues surged 138% year-over-year; company maintains strong balance sheet with over $1B in cash and equivalents
- R&D expenses rose $8M to $81M and SG&A increased $7M to $48M year-over-year, reflecting investment in pipeline expansion
- Full-year 2026 PKD revenue guidance set at $45-50M; multiple pipeline catalysts expected including regulatory submissions and trial data
- Stock rose 4.88% in premarket to $24.80; analyst price targets range $28-$60, suggesting significant upside from current levels
Last Updated: 29-04-2026, 06:36 pm
Read Full TranscriptEarnings
Latest Release
29-04-2026
EPS / Forecast
-1.69 / -1.81
Revenue / Forecast
18.8M / 13.91M
Compare AGIO to Peers and Sector
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.9x | −2.6x | −0.5x | |
PEG Ratio | 0.02 | −0.04 | 0.00 | |
Price/Book | 1.4x | 2.0x | 2.6x | |
Price / LTM Sales | 24.8x | 9.3x | 3.2x | |
Upside (Analyst Target) | 34.7% | 167.9% | 48.8% | |
Fair Value Upside | Unlock | 14.8% | 6.9% | Unlock |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Agios Pharm (AGIO) Share Price Today?
The Agios Pharm share price today is 28.00.
What is the current Agios Pharm (AGIO) share price and day range?
As of 01-05-2026, the Agios Pharm share price is 28.00, with a previous close of 28.00. The share price has ranged from 27.71 to 28.68 today, while the 52-week range spans from 22.24 to 46.00.
What Is the Agios Pharm Market Cap?
As of today, Agios Pharm market cap is 1.64B.
What Is the Agios Pharm (AGIO) Share Price Target?
The average 12-month share price target for Agios Pharm is 41.13, with a high estimate of 60 and a low estimate of 28. 7 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +46.88% Upside potential.
What Is Agios Pharm's Earnings Per Share (TTM)?
The Agios Pharm EPS (TTM) is -7.26.
When Is the Next Agios Pharm Earnings Date?
Agios Pharm will release its next earnings report on 30-07-2026.
From a Technical Analysis Perspective, Is AGIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
How Many Times Has Agios Pharm Stock Split?
Agios Pharm has split 0 times.
How Many Employees Does Agios Pharm Have?
Agios Pharm has 540 employees.
What Is the AGIO Premarket Price?
AGIO's last pre-market stock price is 27.79. The pre-market share volume is 20.00, and the stock has changed by -0.21, or -0.75%.
What Is the AGIO After Hours Price?
AGIO's last after hours stock price is 27.46, the stock has changed by -0.54, or -1.93%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.